Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Background Selinexor combined with dexamethasone has shown activity in patients with
heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral …

Pancreatic cancer is a devastating disease with very poor prognosis. Currently, surgery
followed by adjuvant chemotherapy represents the only curative option which, unfortunately …

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …

Abstract Background Proteasome inhibitors (PIs), including carfilzomib, potentiate the
activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) …

Therapeutic regimens for previously treated multiple myeloma (MM) may not provide
prolonged disease control and are often complicated by significant adverse events …

Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course
characterized by multiple relapses and treatment refractoriness. While recent treatment …

Multiple myeloma continues to be a challenging disorder to treat despite improved therapies
and the widespread use of proteasome inhibitors and immunomodulatory drugs. Although …

Simple Summary Immunotherapy-based treatments have brought many new options in the
treatment of multiple myeloma; still, the disease will inevitably relapse as it remains …

Introduction Therapy for patients with multiple myeloma has improved dramatically over the
past decade following the introduction of novel agents and combinations across the disease …